AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Qlarity Imaging Adds Breast MRI Biopsy Guidance to QuantX, Creating the First End-to-End Solution for Radiologists

November 19, 2019

CHICAGO--(BUSINESS WIRE)--Nov 19, 2019--

Qlarity Imaging, which developed the first FDA-cleared computer-aided breast cancer diagnostic system, announced today it will introduce complementary software to support radiologists in MRI-guided procedures. The clearance effectively makes QuantX the first end-to-end MRI solution of its kind.

The QuantX Breast MRI Biopsy Guidance Plugin — which received 510(k) clearance from the U.S. Food & Drug Administration — expands the capabilities of Qlarity Imaging’s innovative artificial intelligence tool. QuantX now has the capacity to aid radiologists in breast lesion detection, diagnosis and biopsy guidance.

“Expanding QuantX to provide biopsy guidance addresses the need for a solution that supports multiple steps in the patient journey,” said Meg Harrison, Chief Operating Officer of Qlarity Imaging.

The newly-announced module will assist radiologists in planning MRI-guided interventions. It uses information from MRI images to calculate the precise location and depth of the targeted lesion, as well as the recommended location and depth for inserting a biopsy needle. This builds on QuantX’s existing ability to improve radiologists’ interpretations of medical images through an AI algorithm, which provides a single numeric value, called a QuantX Score TM, related to the probability of malignancy.

“Radiologists now have a comprehensive AI-enabled solution for breast MR image review and procedures,” said radiology professor Gillian Newstead, M.D., advisor to Qlarity Imaging. “QuantX has improved our ability to identify and diagnose regions of interest, and now supports biopsy procedures too.”

A clinical study demonstrated the effectiveness of QuantX at helping radiologists interpret cancerous and non-cancerous breast lesions, leading to a 39% reduction in missed breast cancers without a reduction in specificity, as well as a 20% overall diagnostic improvement.

About Qlarity Imaging:

Qlarity Imaging improves patient care by building AI-driven products that provide clinical insights radiologists do not have access to today. One of Qlarity’s initial products, QuantX, is the first FDA-cleared computer-aided diagnosis software for radiology. QuantX integrates images from multiple modalities to assist radiologists in the assessment and characterization of breast abnormalities.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191119005245/en/

CONTACT: Rachel Lenke

847-436-1708

rlenke@kivvit.com

KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS

INDUSTRY KEYWORD: SOFTWARE RADIOLOGY ONCOLOGY HEALTH FDA MEDICAL DEVICES TECHNOLOGY CLINICAL TRIALS

SOURCE: Qlarity Imaging

Copyright Business Wire 2019.

PUB: 11/19/2019 07:00 AM/DISC: 11/19/2019 07:01 AM

http://www.businesswire.com/news/home/20191119005245/en